ABSTRACT
Mycoplasma genitalium (MG) was first isolated by Tully from the urinary tract of the male patient with non-gonococcal urethritis (NGU) in 1981. MG is extremely difficult to be cultured and was rarely studied until the development and application of molecular biology technology. The research on MG in China is still in the primary stage. However, relevant studies abroad have found that it is an important pathogen causing human genitourinary tract infection and spreading worldwide. Male MG infection is reportedly related to NGU, prostatitis, epididymitis, balanoposthitis, male HIV infection, and male infertility. This review outlines the advances in the studies of MG in male urogenital diseases.
Subject(s)
Humans , Male , Balanitis , Microbiology , China , Epididymitis , Microbiology , HIV Infections , Microbiology , Male Urogenital Diseases , Microbiology , Mycoplasma Infections , Mycoplasma genitalium , Urethritis , MicrobiologyABSTRACT
OBJECTIVE:To discuss the economic effectiveness of different therapeutic schemes for the same disease.METH_ODS:104 cases of female's urogenital tract infections of gonococcus combining chlamydia were randomly divided into five gro_ups,which were given ofloxacin(A),levofloxacin hydrochloride(B),clarithromycin(C),azithromycin(D)and ceftriaxone+erythromycin(E)respectively.Using pharmacoeconomic cost-effectiveness analysis method,the five schemes were compared.RES_ULTS:The costs of the five schemes were RMB 351,390,474,633 and 666 yuans,respectively.The ratios between cost and effectiveness were 5.7,4.5,5.5,7.6 and 8.3 in term of curative rate and 4.9,4.1,5.2,7.1 and 7.8 in term of effective rate respectively.CONCLUSION: B and C schemes are the best ones.